| Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact P Baliakas, S Jeromin, M Iskas, A Puiggros, K Plevova, F Nguyen-Khac, ... Blood, The Journal of the American Society of Hematology 133 (11), 1205-1216, 2019 | 235 | 2019 |
| Direct pharmacological targeting of a mitochondrial ion channel selectively kills tumor cells in vivo L Leanza, M Romio, KA Becker, M Azzolini, L Trentin, A Manago, ... Cancer cell 31 (4), 516-531. e10, 2017 | 149 | 2017 |
| Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL A Agathangelidis, A Chatzidimitriou, K Gemenetzi, V Giudicelli, ... Blood, The Journal of the American Society of Hematology 137 (10), 1365-1376, 2021 | 107 | 2021 |
| Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) FR Mauro, D Giannarelli, CM Galluzzo, C Vitale, A Visentin, C Riemma, ... Leukemia 35 (3), 737-746, 2021 | 79 | 2021 |
| COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study T Chatzikonstantinou, A Kapetanakis, L Scarfò, G Karakatsoulis, D Allsup, ... Leukemia 35 (12), 3444-3454, 2021 | 76 | 2021 |
| Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy A Visentin, N Compagno, F Cinetto, S Imbergamo, R Zambello, F Piazza, ... Haematologica 100 (12), e515, 2015 | 62 | 2015 |
| Peripheral nervous system involvement in lymphomas C Briani, A Visentin, M Campagnolo, A Salvalaggio, S Ferrari, T Cavallaro, ... Journal of the Peripheral Nervous System 24 (1), 5-18, 2019 | 57 | 2019 |
| Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival V Trimarco, E Ave, M Facco, G Chiodin, F Frezzato, V Martini, C Gattazzo, ... Oncotarget 6 (39), 42130, 2015 | 53 | 2015 |
| In chronic lymphocytic leukemia the JAK2/STAT3 pathway is constitutively activated and its inhibition leads to CLL cell death unaffected by the protective bone marrow … F Severin, F Frezzato, A Visentin, V Martini, V Trimarco, S Carraro, ... Cancers 11 (12), 1939, 2019 | 47 | 2019 |
| Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases E De Menis, A Visentin, D Billeci, P Tramontin, S Agostini, E Marton, ... Journal of endocrinological investigation 24, 92-97, 2001 | 45 | 2001 |
| In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics GM Rigolin, E Saccenti, E Guardalben, M Cavallari, L Formigaro, ... British Journal of Haematology 181 (2), 229-233, 2018 | 44 | 2018 |
| The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy F Castellani, A Visentin, M Campagnolo, A Salvalaggio, M Cacciavillani, ... Neurology: Neuroimmunology & Neuroinflammation 7 (4), e720, 2020 | 42 | 2020 |
| Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from italian hematology centers S Cantoni, M Carpenedo, MG Mazzucconi, V De Stefano, V Carrai, ... American Journal of Hematology, 2017 | 42 | 2017 |
| HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia F Frezzato, F Raggi, V Martini, F Severin, V Trimarco, A Visentin, ... International journal of cancer 145 (11), 3089-3100, 2019 | 41 | 2019 |
| Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study P Mondello, N Steiner, W Willenbacher, I Wasle, F Zaja, R Zambello, ... Annals of Hematology 95, 1107-1114, 2016 | 41 | 2016 |
| The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia A Visentin, L Bonaldi, GM Rigolin, FR Mauro, A Martines, F Frezzato, ... British journal of cancer 121 (2), 150-156, 2019 | 40 | 2019 |
| The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation A Visentin, L Bonaldi, GM Rigolin, FR Mauro, A Martines, F Frezzato, ... Haematologica, 2021 | 39 | 2021 |
| Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells V Martini, C Gattazzo, F Frezzato, V Trimarco, M Pizzi, G Chiodin, ... British journal of haematology 178 (1), 81-93, 2017 | 37 | 2017 |
| Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia A Visentin, M Facco, F Frezzato, M Castelli, V Trimarco, V Martini, ... Clinical Lymphoma Myeloma and Leukemia 15 (10), 612-620. e5, 2015 | 36 | 2015 |
| Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs C Vitale, C Salvetti, V Griggio, M Porrazzo, L Schiattone, G Zamprogna, ... Blood, The Journal of the American Society of Hematology 137 (25), 3507-3517, 2021 | 35 | 2021 |
Federica FrezzatoDepartment of Medicine - Padua UniversityEmail verificata su unipd.it
